查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1701666

全球家庭检测 (LDT) 市场：产业分析、规模、份额、成长、趋势和预测（2025-2032 年）

Laboratory Developed Test Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
出版日期: | 出版商: Persistence Market Research | 英文 319 Pages | 商品交期: 2-5个工作天内

价格
简介目录

主要发现

  • 家庭自控测试（LDT）市场规模：90亿美元（2025年）
  • 预计市场价值：139亿美元（2032年）
  • 全球市场成长率：6.4%（2025年至2032年的复合年增长率）

上门检测（LDT）市场 - 报告范围

家庭准备测试（LDT）市场包括在单一实验室内设计、製造和使用的诊断测试。当不存在商业性可用的替代品时，这些测试尤其重要，为独特的患者群体和新出现的健康威胁提供量身定制的解决方案。 LDT广泛应用于肿瘤学、遗传学、感染疾病、罕见疾病等专科诊断领域。个人化医疗需求的不断增长、慢性病和感染疾病的流行以及分子诊断技术的进步是推动市场成长的主要因素。

市场成长动力

多种因素推动了全球送货上门检测 (LDT) 市场的成长。个人化医疗的快速发展和客製化诊断解决方案的需求正在推动 LDT 的采用。技术进步，特别是分子诊断和次世代定序的技术进步，显着提高了这些测试的速度、准确性和可靠性。此外，全球癌症、遗传疾病和感染疾病负担的不断加重也增加了对专业化和弹性诊断方案的需求。 COVID-19 疫情进一步凸显了快速、适应性诊断工具的重要性，并提高了人们对 LDT 的认识和监管支持。诊断研究的投资不断增加，以及学术实验室在开发新型检测方法方面发挥的日益重要的作用，也有助于推动市场向前发展。

市场限制

儘管送货上门检测 (LDT) 市场具有诸多优势，但它也面临一些挑战。一个主要问题是各地区缺乏统一的法律规范，这可能导致测试品质和病人安全的差异。即将出台的监管变化，特别是美国提案的《VALID法案》下的变化，可能会给实验室带来更大的合规负担，增加营运成本并限制创新。此外，LDT 通常需要大量的专业知识和基础设施，这限制了其广泛应用，尤其是在资源匮乏的环境中。对可重复性、验证和标准化的担忧进一步阻碍了其广泛采用。最后，来自 FDA核准的商业测试的竞争可能会减少 LDT 在某些应用中的市场占有率。

市场机会

由于诊断技术的不断创新和精准医疗的扩展，LDT 市场提供了巨大的成长机会。人工智慧和生物资讯学日益融入临床测试，为开发更准确、更有效率的测试提供了新的可能性。医疗基础设施和诊断能力的改善，特别是在亚太地区和拉丁美洲等新兴经济体，为 LDT 的采用铺平了新的道路。此外，随着对早期疾病检测和标靶治疗的需求不断增长，LDT 在罕见疾病和药物基因组学等利基诊断领域具有发挥核心作用的优势。此外，学术研究中心和商业诊断公司之间的合作可能会加速 LDT 的发展和市场覆盖。

本报告研究了全球送货上门测试 (LDT) 市场，并对市场动态进行了详细分析，包括成长动力、趋势、机会和挑战。

目录

第一章执行摘要

第二章 市场概述

  • 市场范围和定义
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
    • 主要趋势
  • 宏观经济因素
    • 全球产业展望
    • 全球GDP成长前景
  • COVID-19影响分析
  • 预测因子－相关性和影响力

第三章 增值考虑

  • 产品采用分析
  • 监管格局
  • 赎回方案
  • PESTLE分析
  • 主要企业促销策略

第四章 全球家庭考试（LDT）展望

  • 主要亮点
    • 市场规模及与前一年同期比较
    • 绝对的商机
  • 市场规模分析及预测
    • 市场规模表现分析（2019-2024）
    • 当前市场规模分析与预测（2025-2032）
  • 全球家庭考试（LDT）展望：考试类型
    • 简介/主要发现
    • 按测试类型分類的市场规模绩效分析（2019-2024）
    • 按测试类型分類的当前市场规模分析和预测（2025-2032）
    • 市场吸引力分析：测试类型
  • 全球家庭考试 (LDT) 展望：应用
    • 简介/主要发现
    • 按应用分類的市场规模表现（2019-2024）
    • 目前市场规模分析及应用预测（2025-2032）
    • 市场吸引力分析：应用
  • 全球家庭考试 (LDT) 展望：最终用户
    • 简介/主要发现
    • 最终用户的市场规模表现（2019-2024）
    • 目前市场规模分析及最终用户预测（2025-2032）
    • 市场吸引力分析：最终用户

5. 全球家庭考试（LDT）展望－地区

  • 主要亮点
  • 市场规模绩效分析：按地区（2019-2024）
  • 目前市场规模分析及各地区预测（2025-2032）
    • 北美洲
    • 欧洲
    • 东亚
    • 南亚和大洋洲
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：地区

6. 北美家庭考试（LDT）展望

7. 欧洲家庭考试（LDT）展望

第八章 东亚家庭考试（LDT）展望

9. 南亚和大洋洲家庭考试（LDT）展望

10. 拉丁美洲住宿测试（LDT）展望

11. 中东和非洲家庭考试（LDT）展望

第十二章竞争格局

  • 市场占有率分析（2025年）
  • 市场结构
    • 竞争强度图：按市场
    • 竞争仪錶板
  • 公司简介（详情－概述、财务状况、策略、最新发展）
    • QIAGEN
    • Thermo Fisher Scientific Inc.
    • Kaneka Eurogentec SA
    • Vastian
    • Roche Diagnostics
    • Adaptive Biotechnologies.
    • Guardant Health, Inc.
    • Smiths Medical
    • Quest Diagnostics
    • Beckman Coulter
    • OPKO Health, Inc.
    • Siemens Medical Solutions USA, Inc.
    • Quanterix
    • Proteomics International

第十三章 附录

简介目录
Product Code: PMRREP3430

Persistence Market Research has recently released a comprehensive report on the global Laboratory Developed Test (LDT) Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Laboratory Developed Test Market Size (2025E): US$ 9.0 Bn
  • Projected Market Value (2032F): US$ 13.9 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 6.4%

Laboratory Developed Test Market - Report Scope:

The Laboratory Developed Test (LDT) market encompasses diagnostic tests that are designed, manufactured, and used within a single laboratory. These tests are particularly vital when no commercially available alternatives exist, providing solutions tailored for unique patient populations or emerging health threats. LDTs are widely used in specialized diagnostic areas such as oncology, genetics, infectious diseases, and rare disorders. The increasing demand for personalized medicine, rising prevalence of chronic and infectious diseases, and technological advancements in molecular diagnostics are key contributors to market growth.

Market Growth Drivers:

Several key factors are fueling the growth of the global Laboratory Developed Test market. The rapid rise in personalized medicine and the need for customized diagnostic solutions are encouraging the use of LDTs. Technological advancements, especially in molecular diagnostics and next-generation sequencing, have significantly improved the speed, accuracy, and reliability of these tests. Moreover, the growing burden of cancer, genetic disorders, and infectious diseases globally has amplified the demand for specialized and flexible diagnostic options. The COVID-19 pandemic further highlighted the importance of rapid and adaptable diagnostic tools, driving both awareness and regulatory support for LDTs. Increasing investments in diagnostic research and the growing role of academic and research institutions in developing novel assays also propel the market forward.

Market Restraints:

Despite their advantages, the Laboratory Developed Test market faces several challenges. A key concern is the lack of uniform regulatory oversight across regions, which can lead to variability in test quality and patient safety. The upcoming regulatory changes, particularly in the United States under the proposed VALID Act, could impose stricter compliance burdens on labs, increasing operational costs and limiting innovation. In addition, LDTs often require significant expertise and infrastructure, restricting their widespread use, especially in low-resource settings. Concerns around reproducibility, validation, and standardization further hinder broader adoption. Lastly, competition from FDA-approved commercial tests can reduce the market share for LDTs in certain applications.

Market Opportunities:

The LDT market offers substantial growth opportunities driven by continued innovation in diagnostics and the expanding scope of precision medicine. The increasing integration of artificial intelligence and bioinformatics into laboratory testing presents new possibilities for more accurate and efficient test development. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing improved healthcare infrastructure and diagnostic capabilities, opening up new avenues for LDT adoption. Moreover, as demand grows for early disease detection and targeted therapies, LDTs are well-positioned to play a central role in niche diagnostic areas such as rare diseases and pharmacogenomics. Partnerships between academic research centers and commercial diagnostic companies can also accelerate LDT development and market reach.

Key Questions Answered in the Report:

  • What are the primary factors driving the global Laboratory Developed Test market's growth?
  • Which regions and application areas are experiencing the highest demand for LDTs?
  • How are technological innovations in molecular diagnostics shaping the LDT landscape?
  • Who are the key players in the Laboratory Developed Test market, and what strategies are they adopting to remain competitive?
  • What are the regulatory developments and future projections for the global LDT market?

Competitive Intelligence and Business Strategy:

Leading companies in the global Laboratory Developed Test market, such as Thermo Fisher Scientific Inc., QIAGEN, Roche Diagnostics, and Quest Diagnostics, are focusing on expanding their test portfolios, particularly in oncology, infectious diseases, and genetic testing. These companies are leveraging strategic collaborations with academic institutions, biotech firms, and healthcare providers to enhance innovation and accelerate time-to-market for novel assays. Investment in automation, AI-based data analysis tools, and next-generation sequencing technologies is enabling improved test accuracy and throughput. Furthermore, companies are engaging with regulatory bodies to ensure compliance and support smoother transitions under evolving LDT regulations.

Companies Covered in This Report:

  • Thermo Fisher Scientific Inc.
  • Kaneka Eurogentec S.A.
  • QIAGEN
  • Vastian
  • Roche Diagnostics
  • Adaptive Biotechnologies
  • Guardant Health, Inc.
  • Smiths Medical
  • Quest Diagnostics
  • Beckman Coulter
  • OPKO Health, Inc.

Laboratory Developed Test Market Segmentation:

By Test Type:

  • Clinical Biochemistry
  • Haematology
  • Immunology
  • Microbiology
  • Molecular Diagnostics
  • Others

By Application:

  • Oncology
  • Genetics
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By End User:

  • Hospital Laboratories
  • Specialty Diagnostics Centers
  • Clinical Research Organizations
  • Research Institutes
  • Others

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia and Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Laboratory Developed Test Snapshot, 2025-2032
  • 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Key Trends
  • 2.3. Macro-Economic Factors
    • 2.3.1. Global Sectorial Outlook
    • 2.3.2. Global GDP Growth Outlook
  • 2.4. COVID-19 Impact Analysis
  • 2.5. Forecast Factors - Relevance and Impact

3. Value Added Insights

  • 3.1. Product Adoption Analysis
  • 3.2. Regulatory Landscape
  • 3.3. Reimbursement Scenario
  • 3.4. PESTLE Analysis
  • 3.5. Promotional Strategies, By Key Players

4. Global Laboratory Developed Test Outlook

  • 4.1. Key Highlights
    • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
    • 4.1.2. Absolute $ Opportunity
  • 4.2. Market Size (US$ Bn) Analysis and Forecast
    • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
    • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
  • 4.3. Global Laboratory Developed Test Outlook: Test Type
    • 4.3.1. Introduction / Key Findings
    • 4.3.2. Historical Market Size (US$ Bn) Analysis, By Test Type, 2019-2024
    • 4.3.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
      • 4.3.3.1. Clinical Biochemistry
      • 4.3.3.2. Hematology
      • 4.3.3.3. Immunology
      • 4.3.3.4. Microbiology
      • 4.3.3.5. Molecular Diagnostics
      • 4.3.3.6. Others
    • 4.3.4. Market Attractiveness Analysis: Test Type
  • 4.4. Global Laboratory Developed Test Outlook: Application
    • 4.4.1. Introduction / Key Findings
    • 4.4.2. Historical Market Size (US$ Bn), By Application, 2019-2024
    • 4.4.3. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
      • 4.4.3.1. Oncology
      • 4.4.3.2. Genetics
      • 4.4.3.3. Infectious Diseases
      • 4.4.3.4. Autoimmune Disorders
      • 4.4.3.5. Other Conditions
    • 4.4.4. Market Attractiveness Analysis: Application
  • 4.5. Global Laboratory Developed Test Outlook: End User
    • 4.5.1. Introduction / Key Findings
    • 4.5.2. Historical Market Size (US$ Bn), By End User, 2019-2024
    • 4.5.3. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
      • 4.5.3.1. Hospital Laboratories
      • 4.5.3.2. Specialty Diagnostics Centers
      • 4.5.3.3. Clinical Research Organizations
      • 4.5.3.4. Research Institutes
      • 4.5.3.5. Others
    • 4.5.4. Market Attractiveness Analysis: End User

5. Global Laboratory Developed Test Outlook: Region

  • 5.1. Key Highlights
  • 5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
  • 5.3. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. East Asia
    • 5.3.4. South Asia and Oceania
    • 5.3.5. Latin America
    • 5.3.6. Middle East & Africa
  • 5.4. Market Attractiveness Analysis: Region

6. North America Laboratory Developed Test Outlook

  • 6.1. Key Highlights
  • 6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 6.2.1. By Country
    • 6.2.2. By Test Type
    • 6.2.3. By Application
    • 6.2.4. By End User
  • 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 6.3.1. U.S.
    • 6.3.2. Canada
  • 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 6.4.1. Clinical Biochemistry
    • 6.4.2. Hematology
    • 6.4.3. Immunology
    • 6.4.4. Microbiology
    • 6.4.5. Molecular Diagnostics
    • 6.4.6. Others
  • 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 6.5.1. Oncology
    • 6.5.2. Genetics
    • 6.5.3. Infectious Diseases
    • 6.5.4. Autoimmune Disorders
    • 6.5.5. Other Conditions
  • 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 6.6.1. Hospital Laboratories
    • 6.6.2. Specialty Diagnostics Centers
    • 6.6.3. Clinical Research Organizations
    • 6.6.4. Research Institutes
    • 6.6.5. Others
  • 6.7. Market Attractiveness Analysis

7. Europe Laboratory Developed Test Outlook

  • 7.1. Key Highlights
  • 7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 7.2.1. By Country
    • 7.2.2. By Test Type
    • 7.2.3. By Application
    • 7.2.4. By End User
  • 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 7.3.1. Germany
    • 7.3.2. France
    • 7.3.3. U.K.
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Russia
    • 7.3.7. Turkey
    • 7.3.8. Rest of Europe
  • 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 7.4.1. Clinical Biochemistry
    • 7.4.2. Hematology
    • 7.4.3. Immunology
    • 7.4.4. Microbiology
    • 7.4.5. Molecular Diagnostics
    • 7.4.6. Others
  • 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 7.5.1. Oncology
    • 7.5.2. Genetics
    • 7.5.3. Infectious Diseases
    • 7.5.4. Autoimmune Disorders
    • 7.5.5. Other Conditions
  • 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 7.6.1. Hospital Laboratories
    • 7.6.2. Specialty Diagnostics Centers
    • 7.6.3. Clinical Research Organizations
    • 7.6.4. Research Institutes
    • 7.6.5. Others
  • 7.7. Market Attractiveness Analysis

8. East Asia Laboratory Developed Test Outlook

  • 8.1. Key Highlights
  • 8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 8.2.1. By Country
    • 8.2.2. By Test Type
    • 8.2.3. By Application
    • 8.2.4. By End User
  • 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. South Korea
  • 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 8.4.1. Clinical Biochemistry
    • 8.4.2. Hematology
    • 8.4.3. Immunology
    • 8.4.4. Microbiology
    • 8.4.5. Molecular Diagnostics
    • 8.4.6. Others
  • 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 8.5.1. Oncology
    • 8.5.2. Genetics
    • 8.5.3. Infectious Diseases
    • 8.5.4. Autoimmune Disorders
    • 8.5.5. Other Conditions
  • 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 8.6.1. Hospital Laboratories
    • 8.6.2. Specialty Diagnostics Centers
    • 8.6.3. Clinical Research Organizations
    • 8.6.4. Research Institutes
    • 8.6.5. Others
  • 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Laboratory Developed Test Outlook

  • 9.1. Key Highlights
  • 9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 9.2.1. By Country
    • 9.2.2. By Test Type
    • 9.2.3. By Application
    • 9.2.4. By End User
  • 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 9.3.1. India
    • 9.3.2. Southeast Asia
    • 9.3.3. ANZ
    • 9.3.4. Rest of South Asia & Oceania
  • 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 9.4.1. Clinical Biochemistry
    • 9.4.2. Hematology
    • 9.4.3. Immunology
    • 9.4.4. Microbiology
    • 9.4.5. Molecular Diagnostics
    • 9.4.6. Others
  • 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 9.5.1. Oncology
    • 9.5.2. Genetics
    • 9.5.3. Infectious Diseases
    • 9.5.4. Autoimmune Disorders
    • 9.5.5. Other Conditions
  • 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 9.6.1. Hospital Laboratories
    • 9.6.2. Specialty Diagnostics Centers
    • 9.6.3. Clinical Research Organizations
    • 9.6.4. Research Institutes
    • 9.6.5. Others
  • 9.7. Market Attractiveness Analysis

10. Latin America Laboratory Developed Test Outlook

  • 10.1. Key Highlights
  • 10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 10.2.1. By Country
    • 10.2.2. By Test Type
    • 10.2.3. By Application
    • 10.2.4. By End User
  • 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 10.3.1. Brazil
    • 10.3.2. Mexico
    • 10.3.3. Rest of Latin America
  • 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 10.4.1. Clinical Biochemistry
    • 10.4.2. Hematology
    • 10.4.3. Immunology
    • 10.4.4. Microbiology
    • 10.4.5. Molecular Diagnostics
    • 10.4.6. Others
  • 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 10.5.1. Oncology
    • 10.5.2. Genetics
    • 10.5.3. Infectious Diseases
    • 10.5.4. Autoimmune Disorders
    • 10.5.5. Other Conditions
  • 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 10.6.1. Hospital Laboratories
    • 10.6.2. Specialty Diagnostics Centers
    • 10.6.3. Clinical Research Organizations
    • 10.6.4. Research Institutes
    • 10.6.5. Others
  • 10.7. Market Attractiveness Analysis

11. Middle East & Africa Laboratory Developed Test Outlook

  • 11.1. Key Highlights
  • 11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
    • 11.2.1. By Country
    • 11.2.2. By Test Type
    • 11.2.3. By Application
    • 11.2.4. By End User
  • 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
    • 11.3.1. GCC Countries
    • 11.3.2. Egypt
    • 11.3.3. South Africa
    • 11.3.4. Northern Africa
    • 11.3.5. Rest of Middle East & Africa
  • 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Test Type, 2025-2032
    • 11.4.1. Clinical Biochemistry
    • 11.4.2. Hematology
    • 11.4.3. Immunology
    • 11.4.4. Microbiology
    • 11.4.5. Molecular Diagnostics
    • 11.4.6. Others
  • 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Application, 2025-2032
    • 11.5.1. Oncology
    • 11.5.2. Genetics
    • 11.5.3. Infectious Diseases
    • 11.5.4. Autoimmune Disorders
    • 11.5.5. Other Conditions
  • 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End User, 2025-2032
    • 11.6.1. Hospital Laboratories
    • 11.6.2. Specialty Diagnostics Centers
    • 11.6.3. Clinical Research Organizations
    • 11.6.4. Research Institutes
    • 11.6.5. Others
  • 11.7. Market Attractiveness Analysis

12. Competition Landscape

  • 12.1. Market Share Analysis, 2025
  • 12.2. Market Structure
    • 12.2.1. Competition Intensity Mapping By Market
    • 12.2.2. Competition Dashboard
  • 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 12.3.1. QIAGEN
      • 12.3.1.1. Overview
      • 12.3.1.2. Segments and Test Types
      • 12.3.1.3. Key Financials
      • 12.3.1.4. Market Developments
      • 12.3.1.5. Market Strategy
    • 12.3.2. Thermo Fisher Scientific Inc.
      • 12.3.2.1. Overview
      • 12.3.2.2. Segments and Test Types
      • 12.3.2.3. Key Financials
      • 12.3.2.4. Market Developments
      • 12.3.2.5. Market Strategy
    • 12.3.3. Kaneka Eurogentec S.A.
      • 12.3.3.1. Overview
      • 12.3.3.2. Segments and Test Types
      • 12.3.3.3. Key Financials
      • 12.3.3.4. Market Developments
      • 12.3.3.5. Market Strategy
    • 12.3.4. Vastian
      • 12.3.4.1. Overview
      • 12.3.4.2. Segments and Test Types
      • 12.3.4.3. Key Financials
      • 12.3.4.4. Market Developments
      • 12.3.4.5. Market Strategy
    • 12.3.5. Roche Diagnostics
      • 12.3.5.1. Overview
      • 12.3.5.2. Segments and Test Types
      • 12.3.5.3. Key Financials
      • 12.3.5.4. Market Developments
      • 12.3.5.5. Market Strategy
    • 12.3.6. Adaptive Biotechnologies.
      • 12.3.6.1. Overview
      • 12.3.6.2. Segments and Test Types
      • 12.3.6.3. Key Financials
      • 12.3.6.4. Market Developments
      • 12.3.6.5. Market Strategy
    • 12.3.7. Guardant Health, Inc.
      • 12.3.7.1. Overview
      • 12.3.7.2. Segments and Test Types
      • 12.3.7.3. Key Financials
      • 12.3.7.4. Market Developments
      • 12.3.7.5. Market Strategy
    • 12.3.8. Smiths Medical
      • 12.3.8.1. Overview
      • 12.3.8.2. Segments and Test Types
      • 12.3.8.3. Key Financials
      • 12.3.8.4. Market Developments
      • 12.3.8.5. Market Strategy
    • 12.3.9. Quest Diagnostics
      • 12.3.9.1. Overview
      • 12.3.9.2. Segments and Test Types
      • 12.3.9.3. Key Financials
      • 12.3.9.4. Market Developments
      • 12.3.9.5. Market Strategy
    • 12.3.10. Beckman Coulter
      • 12.3.10.1. Overview
      • 12.3.10.2. Segments and Test Types
      • 12.3.10.3. Key Financials
      • 12.3.10.4. Market Developments
      • 12.3.10.5. Market Strategy
    • 12.3.11. OPKO Health, Inc.
      • 12.3.11.1. Overview
      • 12.3.11.2. Segments and Test Types
      • 12.3.11.3. Key Financials
      • 12.3.11.4. Market Developments
      • 12.3.11.5. Market Strategy
    • 12.3.12. Siemens Medical Solutions USA, Inc.
      • 12.3.12.1. Overview
      • 12.3.12.2. Segments and Test Types
      • 12.3.12.3. Key Financials
      • 12.3.12.4. Market Developments
      • 12.3.12.5. Market Strategy
    • 12.3.13. Quanterix
      • 12.3.13.1. Overview
      • 12.3.13.2. Segments and Test Types
      • 12.3.13.3. Key Financials
      • 12.3.13.4. Market Developments
      • 12.3.13.5. Market Strategy
    • 12.3.14. Proteomics International
      • 12.3.14.1. Overview
      • 12.3.14.2. Segments and Test Types
      • 12.3.14.3. Key Financials
      • 12.3.14.4. Market Developments
      • 12.3.14.5. Market Strategy

13. Appendix

  • 13.1. Research Methodology
  • 13.2. Research Assumptions
  • 13.3. Acronyms and Abbreviations